Movement Alert|Spyre Therapeutics Rises 8.19% in After-Hours Trading, Trading at $105.0

Market Focus
06/24

On June 23, Spyre Therapeutics rose 8.19% in after-hours trading, trading at $105.0/share, with turnover of $4.1119 million.

Within the Biotechnology sector where Spyre Therapeutics belongs, individual stocks showed mixed performance. Among individual stocks, AbbVie down 0.12%, Apogee Therapeutics down 0.14%, Gilead Sciences up 0.32%, Regeneron Pharmaceuticals down 0.33%, Amgen down 0.58%.

Spyre Therapeutics is a preclinical stage biotechnology company focused on developing therapeutics for patients with inflammatory bowel disease. Its pipeline includes SPY001 (anti-a4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) monoclonal antibodies, as well as combination therapies SPY120, SPY130, and SPY230.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10